Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Citi
US Department of Justice
Dow
UBS
US Army
Farmers Insurance
McKinsey
AstraZeneca
Novartis
Deloitte

Generated: August 18, 2017

DrugPatentWatch Database Preview

FASLODEX Drug Profile

« Back to Dashboard

Which patents cover Faslodex, and what generic Faslodex alternatives are available?

Faslodex is a drug marketed by Astrazeneca and is included in one NDA. There are four patents protecting this drug and one Paragraph IV challenge.

This drug has sixty-six patent family members in forty countries.

The generic ingredient in FASLODEX is fulvestrant. There are ten drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the fulvestrant profile page.

Summary for Tradename: FASLODEX

Patents:4
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list53
Clinical Trials: see list106
Patent Applications: see list6,093
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:FASLODEX at DailyMed

Pharmacology for Tradename: FASLODEX

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► SubscribeY► Subscribe
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: FASLODEX

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca
FASLODEX
fulvestrant
INJECTABLE;INTRAMUSCULAR021344-001Apr 25, 2002► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: FASLODEX

Drugname Dosage Strength RLD Submissiondate
fulvestrantInjection50 mg/mL, 2.5 mL and 5 mL syringeFaslodex10/1/2009

International Patent Family for Tradename: FASLODEX

Country Document Number Estimated Expiration
Slovenia1250138► Subscribe
Hong Kong1052884► Subscribe
Czech Republic304689► Subscribe
Slovakia287221► Subscribe
Norway337329► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: FASLODEX

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
04C/004Belgium► SubscribePRODUCT NAME: FULVESTRANT; REGISTRATION NO/DATE: EU/1/03/269/001 20040311
C/GB04/009United Kingdom► SubscribePRODUCT NAME: FULVESTRANT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; REGISTERED: UK EU/1/03/269/001 20040310
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
UBS
US Department of Justice
Queensland Health
Express Scripts
Cerilliant
Argus Health
Julphar
Teva
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot